Clinical Trial Update: Brimonidine 0.33% for Rosacea-Related Facial Erythema [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating brimonidine 0.33% topical gel for rosacea-related facial erythema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rosacea
• Rosacea Subtype

Drugs mentioned

• BRIMONIDINE TARTRATE (brimonidine tartrate)

Snippet

Sponsor: Istanbul Training and Research Hospital | Conditions: Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic) | Phase 4 | Status: COMPLETED